PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

OL.
20
983

Volume contents, Author index
and Subject index to
Volume 20

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
J. Gy Papp—*Szeged, Hungary*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*Cardiff, Wales*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1984, U.S. $800.00 including postage and insurance, 2 years, 1984/85, U.S. $1520.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1984 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproduction, microform or any other reproduction of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical photocopying recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $0.50 per page is paid directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon Office.

The Item-Fee Code for this publication is: 0163-7258/83 $0.00 + 0.50

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 20, 1983, Numbers 1–3

CONTENTS

Number 1 PAGE

Clinical aspects of developmental pharmacology and toxicology: *J. V. Aranda and L. Stern* 1

The ontogeny of the response of the avian embryo heart to autonomic neurotransmitters and to neurotrasmitter-like drugs: *D. Higgins* 53

Hydrotherapy–mechanisms and indications: *P. Franchimont J. Juchmes and J. Lecomte* 79

Beta-adrenergic blocking drugs in the treatment of hypertension: *A. J. Scriven and P. J. Lewis* 95

Pathology of eating: *S. Gilbert* 133

Number 2

Erythrocyte carriers: *G. M. Ihler* 151

Regulation of the allergic response in schistosomiasis: a proposed model: *J. K. Weltman and A. W. Senft* 171

NAG vibrio toxin: *S. C. Sanyal* 183

Calcium antagonists: a new class of drugs: *W. G. Nayler and J. D. Horowitz* 203

Development of glucocorticoid antagonists: *G. P. Chrousos, G. B. Cutler Jr, M. Sauer, S. S. Simons Jr and D. L. Loriaux* 263

Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology: *F. M. Schabel Jr, D. P. Griswold Jr, T. H. Corbett and W. R. Laster Jr* 283

Number 3

Effects of drugs on the respiratory control system in the perinatal period and during postnatal development: *T. Trippenbach* 307

Purine metabolism in the schistosomes: potential targets for chemotherapy: *A. W. Senft and G. W. Crabtree* 341

Calcium ions, drug action and airways obstruction: *B. R. Creese* 357

Magnetic microspheres: a vehicle for selective targeting of drugs: *K. J. Widder and A. E. Senyei* 377

Gastrointestinal absorption of folates and antifolates: *J. Selhub, G. J. Dhar and I. H. Rosenberg* 397

Neurohypophysial hormones and brain function: the neurophysiological effects of oxytocin and vasopressin: *R. E. J. Dyball and A. T. Paterson* 419

Vasopressin and memory: *T. B. van Wimersma Greidanus, J. M. van Ree and D. de Wied* 437

OL.
20
983

AUTHOR INDEX

Aranda, J. V. 1

Chrousos, G. P. 263
Corbett, T. H. 283
Crabtree, G. W. 341
Creese, B. R. 357
Cutler Jr, G. B. 263

Dhar, G. J. 397
Dyball, R. E. J. 419

Franchimont, P. 79

Gilbert, S. 133
Griswold Jr, D. P. 283

Higgins, D. 53
Horowitz, J. D. 203

Ihler, G. M. 151

Juchmes, J. 79

Laster Jr, W. R. 283
Lecomte, J. 79
Lewis, P. J. 95
Loriaux, D. L. 263

Nayler, W. G. 203

Paterson, A. T. 419

Rosenberg, I. H. 397

Sanyal, S. C. 183
Sauer, M. 263
Schabel Jr, F. M. 283
Scriven, A. J. 95
Selhub, J. 397
Senft, A. W. 171, 341
Senyei, A. E. 377
Simons Jr, S. S. 263
Stern, L. 1

Trippenbach, T. 307

van Ree, J. M. 437
van Wimmersma Greidanus, T. B. 437

Weltman, J. K. 171
Widder, K. J. 377
de Wied, D. 437

SUBJECT INDEX

Adenocarcinoma, vagina 15
Adenosine
  analog structures 350
  structure 350
Adenosine kinase in schistosomes 345
Adenosine metabolism, *Schistosoma mansoni* 343
Adenosine phosphorylase in schistosomes 345–7
β-Adrenergic blocking drugs
  adverse effects 122–18
  ancillary properties 111, 112
  baroceptor effects 97, 98
  cardiac failure 112, 113
  cardiovascular mechanisms 96
  central effects 98–100
  central nervous system effects 117
  drug combinations 102
  effects in hypertension 101–11
  hypertension 95–122
  lipid solubility 99
  mechanism of action 96–101
  metabolic side-effects 115, 116
  once-daily 102–5
  pharmacokinetics 103
  receptor distribution and effects 96
  renin activity 100, 101
  respiratory side-effects 115
  Reynaud's phenomenon 113, 114
  slow channel blocking drug interactions 232, 233
  therapeutic uses 95
  withdrawal 114, 115
Adriamycin
  carrier and free distribution *in vivo* 384
  tumor regression 286
  Yoshida sarcoma response 385–7
Adverse drug reactions
  antihypertensives 118–21
  β-blockers 112–18
  slow channel blockers 229–32
Airways obstruction 357–70
Alcohol, fetal effects 17, 18
Aminophylline
  breathing effects 326
  fetal lung maturation 23
Aminopterin 7
AMP, cyclic and arachidonic acid metabolism 367, 368
Ampicillin half-life, post-natal changes 31
Anorexia
  and cancer 133, 134
  depression 134, 135
  elderly 134
  incidence 133
Anorexia nervosa 135, 136
Antiasthmatic drugs and calcium ions 368, 369
Anticancer drugs
  dose dependence and regression 287–90
  doses in combination 298
  increasing therapeutic response 283–303
  individual treatment basis 299–302
  LD_{50} 298
  metabolism, host variability 269–9
  tumor regression 285–9
  two-drug combination 290–6
Anticonvulsants, teratogenicity 12, 13
Antifolates *see also* methotrexate
  brush border membrane vesicles 414–16
  intestinal absorption in animals 408–16
    dose 409
  intestinal absorption in man 406–8
    dose 407, 408
  isolated epithelium study 412, 413
Antiglucocorticoids 263–80
  chronic bioassays 265
  classes and structures 264
  11-deoxycortisol activity 265, 268–71
  dose–response curves 264
  equilibrium dissociation constants 265
  mechanism of action 266, 267
  11-oxa-11-deoxycortisol 272, 273
  receptor assays 266–8
Antihistamines, bioassay 14
Antimicrobial drugs, teratogenicity 12
Antinauseant drugs, teratogenicity 14
Antineoplastic drugs, teratogenicity 11
Apnea and xanthines in preterm infants 330, 331
Arabinosyl-6-mercaptopurine (Ara-6-MP), schistosome effects 349
Ara-C, tumor regression 285, 287
Arachidonic acid metabolism and calcium 367, 368
Asthma
  airways smooth muscle 357, 358, 360–2
  allergic reaction 358, 359
  calcium and smooth muscle 359–62
  drug action and calcium 368–70

Balneotherapy (general hydrotherapy) 79
  consequences 87
  hyperthermia
    effects 85, 86
    methods 84–7
    pathophysiological effects 86, 87
    peloid baths 84, 85
  hypothermia, methods 87
  indications 88, 89
Baroceptors 97, 98
Bendrofluazide, assessment in mild hypertension 119, 120
Binge-eating
  normal weight 142–4
  overweight 139–42
Brain, neurohypophyseal peptide distribution 430–3
Breast milk
  blood transfer of drugs 34, 35
  caffeine 37, 38
  dioxin 39

drug delivery to infants 35
drugs in 35–7
environmental chemicals 38, 39
precautions 39, 40
Breathing
central control 309, 310
control and development 311–13
endogeneous opiates 315, 316, 323–5
experimental study 310, 311
sleep patterns 314, 315
vagal reflexes 313, 314
xanthine effects 325–33

Caffeine
breathing responses 326
milk 37, 38
teratogenicity 18
Calcium
airways smooth muscle regulation 359–62
allergic mediator release 362–4
drug action 368–70
ion channels 205
mast cell action 365, 366
movement in mast cells 364, 365
slow channels 206
slow current in heart muscles 204–6
Calcium antagonists 203–51 *see also* slow channel blockers
asthma 369, 370
binding characteristics 217
binding sites 216
definition 213, 214
dose–response data 215
history 203
myocardial effects 203, 204
organic 212
receptor interactions 220
sites of action 208, 214, 215
substances and formulae 208–13
tissue specificity 220, 221
Cancer cachexia 133
Carbon dioxide baths 93
Cinnarizine structure 212
Cortisol
–21-mesylate, antiglucocorticoid 276–8
structure 269
Cyclophosphamide
and actinomycin D effects 293–5
and 5-fluorouracil effects 295–7
and L-PAM 290, 293, 294
and purine antagonist response 294–6
sarcoma response and dose 288
treatment schedules and activity 302

D-600 structure 210
Daunomycin, adenocarcinoma response 292
11-Deoxycortisol
analog activity 268–76
antiglucocorticoid activity 265–9
structure 269
Developmental pharmacology 1–44
Dexamethasone-oxetanone, antiglucocorticoid activity 276–8
Dieting, pathology 142–4
Digoxin, slow channel blocker actions 233
Dihydropyridine derivatives, formula 210, 211 *see also* nifedipine
Diltiazem
adverse effects 230
dose 226
ischemic heart disease 238
pharmacology 219
structure 204
variant angina pectoris 241
Ductus arteriosus closure 40, 41

Eating *see also* anorexia
overeating 136–42 *see also* binge-eating
causes 139
and obesity 138
pathology 133–46
restraint 144, 145
Embryogenesis, critical periods and drug intake 10, 11
Embryo heart, ontogeny 54–70
acetylcholine response 64
adrenoceptors 58, 59
catecholamine teratology 63, 64
chronotropic responses 59–61, 64, 65
innervation 54
parasympathetic 54–7
sympathetic 57, 58
inotropic response 61–3
muscarinic binding 67–9
nicotinic cholinergic responses 69, 70
ventricular muscle 66, 67
β-Endorphin
breathing control 316, 317
fetus 322–4
newborn 322–4
ventilation 318, 319
Enkephalin
breathing control 316, 317
fetus 322–4
newborn 322–4
ventilation 318, 319
Environmental chemicals in breast milk 38, 39
Erythrocyte carriers 151–65
adenosine deaminase 151, 152
cell fusion 164, 165
desferoxamine 158, 159
DNA carrier 165
DNA target 161, 162
exogenous enzymes 162, 163
Gaucher's disease 159, 160
glucocerebrosidase 160
small molecules 163, 164
thiamine tetrahydrofurfuryldisulfide 161
Erythrocytes
circulating carriers 160, 161
electrical breakdown 154
endocytosis 154
enzyme entrapment 152–4
fluorescent compounds 157
hypo-osmotic lysis 153, 154
metabolism 155
survival of resealed 155–7
Erythrophagocytic cells 157–60

Father, drug ingestion and effects on fetus 9
Fendiline structure 213
Fetus *see also* mother–child pairs
breathing control 311, 312
drug effects 10–17
non-therapeutic 17–19
prevention 20, 21
therapeutic 11–17
drug exposure 7, 8

drug metabolism 4, 5
drug responses, factors affecting 19–21
drug toxicity mechanism 20
endogenous opiates and breathing control 322–4
environmental chemicals 19
enzyme induction 21–4
lung maturation 21–4
maternal drug consumption 8
paternal drug intake 9
placental drug transfer 8, 9
receptor function 3, 4
therapy 21–4
Flunarizine structure 212
2-Fluoro-ara-AMP, colon adenocarcinoma and dose 291
2′-*p*-Fluorophenylpyrazole-11-deoxycortisol
dexamethasone treated rats 274–6
structure 274
5-Fluorouracil
sarcoma dose–response 292
tumour regression 286
Folate *see also* antifolates
brush border membrane vesicle uptake 414–16
intestinal absorption and transport 400–5
concentration dependence 402, 403
pH dependence 401, 402, 403
time-course 401
intestinal metabolism 403
proteins binding 405
reduced, intestinal absorption 405, 406
transport
animals 398–400
clinical 397, 398
competitors 404
energy dependence 404, 405
inhibitors 404
investigations 397
temperature dependence 405
Formycin
schistosome effects 349–52
structure 350

Half-lives, drugs
newborn and adult 28
phenobarbital 29
phenytoin 29
and renal excretion 32
Heart muscle
excitation–contraction coupling 206
slow channel transport, factors affecting 207, 208
activators 209
substances altering 208–13
Hering-Breuer expiratory–promoting reflex 314
Hering-Breuer inspiratory–inhibitory reflex 313, 314
Hibernation, artificial in man 89, 90
Hormones, teratogenicity 15, 16
Hydrotherapy
clinical indications 87, 88
dangers 90
definitions 79
general *see* balneotherapy
local hyperthermia
immunoreactivity 93
indications 88
methods 93
neural effects 81, 82
pathophysiology 82
local hypothermia 82–4, 93
indications 88
mechanisms 83
methods 82
processes benefitting 90
Hyperphagia and hypothalamus 136, 137
Hypertension
β-adrenergic drugs 95–122
black patients 106, 107
elderly patients 107–9
first choice drug 118–21
prognosis 120
pregnancy 109–11
slow channel blockers 242–4
Hypoglycemic drugs, teratogenicity 16

Immunoglobulin E
cross-linking regulation 176
despecification 177–9
–Fc mast cell binding 174, 175
quarternary structure 178
–receptor density in mast cells 173, 174
Ion selective channels 205
Ischemic heart disease and slow channel blocking drugs 233–42

Kleine-Levin syndrome 138
sleep pattern 138

Labetalol
effects in hypertension 105
hypertensive emergencies 106
Learning, hippocampal mechanisms 420, 421
Lidoflazine
dose 226
structure 212
Lung maturation, embryo 22, 23

Mast cell
calcium ion action site 365, 366
calcium ion movements 364, 365
degranulation models 173–7
sensitization and model application 176, 177
MeCCNU, Lewis lung carcinoma response and dose 290
Memory
Brattleboro rats 445, 446
hippocampal mechanisms 420, 421
vasopressin 437–53
6-Mercaptopurine and tumor regression 286
Methotrexate *see also* antifolates
absorption in animals 408–16
kinetic constants 410
pH effects 411, 412
absorption in man 406–8
transport
brush border membrane vesicles 414–16
inhibitors affecting 411, 416
L1210 cells *in vitro* 412, 413
Methylxanthines and neonatal apnea 41, 42
Metyrapone and lung maturation 23
Microspheres, magnetic
adjacent to tumour cell 388, 390
adriamycin release kinetics 381, 382
and temperature 382
adriamycin in Yoshida sarcoma 385–7
distribution *in vivo* 383–92

OL.
20
983

drug targeting 377–94
endothelial cells 389
magnet placement 379
membrane bound in tumor 388, 391
preparation 380–3
tumor cell interactions 388
tumor growth effects 390, 391
Mother–child pairs, drug exposure incidence 9
MRC mild hypertension trial, drugs and side-effects 118–21

Naloxone and breathing control 320, 321, 324, 325
Neurotransmitters, avian embryo heart 53–71
Newborn
absorption of drugs 25, 26
breathing control 312
dose and therapeutic monitoring 31–4
drug half-lives 28, 29
drugs used 24
endogenous opiates and breathing control 322–4
gastric acids 26
pharmacokinetics 27, 30
protein binding of drugs 26, 27
receptor sites 25
renal drug excretion 30, 31
therapy and approaches 40–3
Nifedipine 204, 219, 220
adverse effects 230
angina pectoris 237, 238
variant 240
dose 226
hypertension, acute effects 243
myocardial effects 219
structure 204, 211
Niludipine structure 211
Nimodipine structure 211
Nitrendipine binding, calcium antagonist inhibition 217

Oculomucocutaneous syndrome 116, 117
Opiates, endogenous and breathing control 315–21
adults 316
11-Oxa-11-deoxycortisol
antiglucocorticoid activity 272
effect on dexamethasone treated rats 272–4
structure 272
Oxygen toxicity, pharmacological approaches 42–4
Oxytocin
cell multiple unit recordings 423, 424
continuously firing cells 430
distribution and function 419, 420
glutamate driven neurone effects 432
neural mechanisms and behavioral effects 420–2
neuromodulator/neurotransmitter role 423–32
peptidergic cells in magnocellular nuclei 424–9
response modulation 422

PalmO-ara-C
colon adenocarcinoma and dose 291
sarcoma response 285
Papavarine derivatives 210 *see also* verapamil
Perhexiline
adverse effects 230, 231
angina pectoris 237
dose 226
structure 213
Pharmacokinetics
β-adrenergic blockers 103
newborn 27, 28
Pharmacology
developmental 1–44
fetus 1–5
Phenobarbital, half-lives in infants and adults 28, 29
L-Phenylalanine mustard dose, sarcoma response 289
Phenytoin, half-lives in infants 28, 29
Piperazine derivatives 211–13
Placenta drug transfer 2, 3, 8, 9
Prader–Willi syndrome 137, 138
Pregnancy, hypertension 109–11
Prenylamine structure 213
Propranolol
angina pectoris 236
assessment in mild hypertension 119, 120
Prostaglandins and ductus arteriosus 40, 41
Psychotropic drugs, teratogenicity 13, 14
Purine analogs *see also* adenosine
incorporation rates, *Schistosoma mansoni* 352, 353
nucleotide synthesis effects 351, 352
Purine metabolism
analog effects 347–54
research strategies and screening 354, 355
schistosomes 341–55
analog incorporation 345
enzyme scheme 341, 342
multiple analogue use 354, 355
pathways 343

Raynaud's phenomenon and β-blockers 113, 114
Receptors
distribution of adreno- 96
glucocorticoid binding 266–8
Renin activity and β-blocking agents 100, 101
Respiratory control system, drug effects 307–33
Respiratory neurons
dorsal group 307
organization 307–9
pontine 307, 308
ventral group 307

Sauna 89
Schistosomes
adenosine metabolism 346
in vitro purine enzyme excretion 343, 344
multiple analog effects 353, 354
purine analog effects 347–54
purine metabolism and chemotherapy 341–55
Schistosomiasis
allergic response modulation 171–9
basis 172
IgE 172, 173
skin test 173, 179
host responses 171
mast cell degranulation 173–7
Sclerosing peritonitis 117

Sereny's test, *Shigella flexneri* and NAG vibrios 196
Serum levels
  anticancer drug determination 301, 302
  drugs and clinical response 300
Severe combined immunodeficiency disease (SCID)
  erythrocyte use 151, 152
Sinus node dysfunction 114
Skin tests, schistosomiasis 173, 179
SLE syndrome, β-blocking drugs 117
Slow channel blockers *see also* calcium antagonists
  asthma 250
  calcium antagonists 216
  cardiac arrhythmias 248–50
  cardiac failure 244, 245
  consequences of inhibition 222
  dosage 226
  drug interactions 232, 233
  heart conduction tissue 222, 223
  hypertension 242–4
  hypertrophic cardiomyopathy 245–8
  ischemic heart disease 233–42
  labyrinthine disease 250
  myocardial infarction 242
  non-cardiovascular effects 225
  pharmacodynamic effects 223–5
  pharmacokinetics 227–9
  vascular smooth muscle effects 220–2
Smoking, fetal effects 18

Targeting *see also* erythrocytes, microspheres
  ideal carrier 377
  magnetic 379
  objectives 377
  systems 377–9
Teratogenicity
  drugs 11–17
  human models 5–7
Terodiline structure 213
Tetrodotoxin, sites of action 209
Thalidomide embryopathy 5
  critical period 6
  dose 5
Theophylline
  breathing control 331, 332
  muscle contraction 328
Therapeutic monitoring and dose in newborn 31–4
6-Thioguanosine
  adenosine metabolism in schistosomess 348, 349
  structure 350
Toxicology, developmental 1–44
Tubericidin
  mechanism of action 348
  purine analog in schistosomes 347
  structure 350
Tumor
  growth curve 284
  regression responses 285–7
    adenocarcinoma 287
    drug dose 287–96
    magnetic microspheres 391, 392
    sarcoma 285, 286
  sarcoma
    cyclophosphamide dose 288
    4-phenylalanine mustard dose 289

Vasopressin
  acquisition 440
  avoidance behavior 448–50
    active 437, 438
    passive 438, 439
  amnesia 439, 440
  antiserum, intracerebroventricular administration 447, 448
  blood levels and behavior 443–5
  constant collision stimulation 426, 427
  diabetes insipidus rates 445–7
    memory loss 446
  distribution and function 419, 420
  drug intake 452
  EEG theta thythm 424
  endogenous and behavior 443–5
  hippocampal cell firing 431
  human brain function 450–2
  intracerebroventricular administration 441, 442
  memory 437–53
  neural mechanisms and behavioral effects 420–2
  neurone inhibition 425
  neurotransmitter role 426, 428
  receptor blocker 431
  response modulation 422
  retrieval processes 447
  sites of action 448–50
  spinal cord neuron depolarization 433
  structure–activity 442, 443
  supraoptic nucleus explant 428
Ventilation, chemical control 312, 313
Ventricular action potential, ionic fluxes 205
Verapamil
  adverse effects 229, 230
  angina pectoris 235–7
    variant 241
  dose 226
  isomer properties 218
  pharmacokinetics 227, 228
  structure 204, 210
Vibrio cholerae and NAG toxin
  antibody response 184
  culture filtrate effects 190
  diarrhea 183, 184
  diseases caused 184
  enterotoxigenicity 185–92
    cells and rabbit ileal loop 185–7
    cholera enterotoxin 193–5
    culture filtrate 188
    Escherichia coli LT toxin 195
    ileal loop enhancement 187
    infant rabbit model 188
    mode of action 197, 198
    pH effects 193
    toxin nature 192, 193
  features 184
  first report 183
  hemorrhagic principle 189–91
  invasiveness 196, 197
  skin vascular permeability factor 189, 190
  sources 187
  suckling mouse assay 191
  tissue culture 191, 192
Vincristine
  sarcoma response 293
  tumor regression 286
Vitamins, teratogenicity 16
Vitamin E, antioxidant effect 43, 44

Warfarin, teratogenicity 17

Xanthines
breathing control 325–33
cholinesterase inhibition 329
excitatory effects 327
mechanisms of action 325–9
perinatal effects 329–33
preterm infants 330

PHARMACOLOGY & THERAPEUTICS

Aims and Scope

Pharmacology and Therapeutics presents lucid, critical and authoritative reviews of currently important topics in pharmacology. The articles are normally specially commissioned, although uninvited review papers are occasionally published. When all the manuscripts covering a certain topic have been published, they are reappraised and, if necessary, updated, and then published as a definitive hard bound volume of the *International Encyclopedia of Pharmacology and Therapeutics*.

This policy ensures that each article is published immediately and is not delayed by the later arrival of other manuscripts for the Encyclopedia volume.

Invitation to Authors

Uninvited reviews will be welcomed for editorial consideration and authors should write to the relevant Executive Editor to obtain guidance on how to prepare their manuscripts prior to submitting their reviews.

International Encyclopedia of Pharmacology and Therapeutics—Editorial Board

W. C. Bowman—*Strathclyde*
D. C. Bovet—*Rome*
A. M. Breckenridge—*Liverpool*
A. S. V. Burgen—*London*
J. Cheymol—*Paris*
G. B. Koelle—*Philadelphia*
P. Lechat—*Paris*
H. Rašková—*Prague*
A. C. Sartorelli—*New Haven*
V. V. Zakusov—*Moscow*

Some Recent and Forthcoming Encyclopedia Volumes

Section 107 Inhibitors of Mitochondrial Function
Editors: *M. Erecinska and D. F. Wilson*
ISBN 0 08 027380 7 348pp

Section 108 Hepatic Cytochrome P-450 Monooxygenase System
Editors: *J. B. Schenkman and D. Kupfer*
ISBN 0 08 027381 5 864pp

Section 109 Anti-Hypertensive Drugs
Editor: *A Doyle*
ISBN 0 08 028849 9 260pp

Section 110 The Chemotherapy of Psoriasis
Editor: *H. P. Baden*
ISBN 0 08 029823 0 310pp

Section 111 Antiviral Chemotherapy, Vol 1
Editor: *D. Shugar*
ISBN 0 08 029821 4 504pp

Section 112 Pain and Its Management
Editors: *N. E. Williams and H. Wilson*
ISBN 0 08 029822 2 120pp

Section 113 Differentiation Toxicities of Insecticides and Halogenated Aromatics
Editor: *F. Matsumura*
ISBN 0 08 029826 5 560pp

Subscribers to the Journal Pharmacology and Therapeutics may purchase individual volumes of the encyclopedia at a 20% reduction on the published price.

Send to your nearest Pergamon Office for details.